Trial Profile
Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial skin diseases; Gram-positive infections; Skin infections
- Focus Adverse reactions
- Acronyms ABSSSI
- Sponsors Allergene
- 21 Jan 2019 Status changed from active, no longer recruiting to completed.
- 10 Oct 2018 Planned End Date changed from 30 Sep 2018 to 31 Oct 2018.
- 10 Oct 2018 Planned primary completion date changed from 30 Sep 2018 to 31 Oct 2018.